KLISYRI® (tirbanibulin) is Now FDA Approved. Learn more

Recent News

Athenex Presents Data on Oral Docetaxel and Oral Paclitaxel at ASCO2021 Virtual Scientific Program

Athenex Announces Klisyri® (tirbanibulin) Receives Positive CHMP Opinion from the European Medicines Agency (EMA) for the Treatment of Actinic Keratosis of the Face or Scalp

Athenex, Texas Children’s Cancer Center, and the Center for Cell and Gene Therapy at Baylor College of Medicine Present New Clinical Data on GD2 CAR-NKT Cells in Neuroblastoma at ASGCT Annual Meeting

Athenex Provides First Quarter 2021 Corporate and Financial Update

Athenex to Acquire Kuur Therapeutics to Expand Cell Therapy Development with Off-the-Shelf Engineered CAR-NKT Platform

Athenex to Provide Corporate and Financial Update for the First Quarter 2021 on May 6, 2021

Athenex Provides Fourth Quarter and Full Year 2020 Corporate and Financial Update

Athenex Receives FDA Complete Response Letter for Oral Paclitaxel Plus Encequidar for the Treatment of Metastatic Breast Cancer

Athenex to Provide a Corporate and Financial Update for the Fourth Quarter and Full Year 2020 on March 1, 2021

Our Science

We are focused on discovering and developing novel therapies for treating cancer and addressing unmet medical needs.
Learn more

Investors

View press releases, events and presentations, and other investment information.
Learn more

Join Our Team

As the Company grows, we are always looking to add talented professionals to join the Athenex family.
Learn more

Other Highlights

Photography by Christopher Galluzzo / Nasdaq, Inc.

Photography by Christopher Galluzzo / Nasdaq, Inc.

On June 14, 2017, Athenex celebrated its initial public offering (IPO) at the Nasdaq MarketSite in Times Square.
Athenex is building a 409,000 square foot manufacturing facility in Dunkirk, NY, with support from New York State.